Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer

Recruiting now

Conditions studied: Colorectal Cancer, Colorectal Adenoma

In brief

CoLiQ is a clinical study designed to evaluate the clinical usefulness of circulating tumor DNA (ctDNA) markers found in blood, as a liquid biopsy for diagnosis, prognosis and follow-up of colorectal cancer. The main questions it aims to answer are: 1) Can a panel of ctDNA markers identify CRC patients among the other patients summoned for colonoscopy? and 2) Does the type, number and level of ctDNA markers vary with the subtype and clinical course of CRC? Participants will be asked to answer a questionnaire and give a blood sample at inclusion. In addition, patients with CRC will be asked to give an extra test tube at their routine treatment and follow-up blood sampling.

Key facts

Study ID

NCT06307938

Run by

Helse Nord-Trøndelag HF

People needed

3000

Starts

2025-03-10

Expected to finish

2028-05-01

Last updated by the study team

2025-04-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patient ≥ 18 years old summoned for colonoscopy
• Patient able to understand and sign written informed consent

You may not qualify if…

• Patient < 18 years old
• Patient unable to understand or give written informed consent
• Patient unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the investigator as unlikely to complete the study

Where it is running

• Nord-Trøndelag Hospital Trust — Levanger, Norway (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.